Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant Influenza Vaccine in NHL Patients
NCT00307710Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2004
- Primary completion
- Feb 2007
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of influenza vaccine (recombinant) in influenza (4 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Immunogenic response (4-fold or greater increase in serum antibody) at 8 weeks. Started Aug 2004; status: completed.
02
Drugs
influenza vaccine (recombinant)
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00307710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00307710.